PMID- 23857458
OWN - NLM
STAT- MEDLINE
DCOM- 20140502
LR  - 20211021
IS  - 1619-7089 (Electronic)
IS  - 1619-7070 (Linking)
VI  - 40
IP  - 11
DP  - 2013 Oct
TI  - High (1)(2)(3)I-MIBG uptake in neuroblastic tumours indicates unfavourable 
      histopathology.
PG  - 1701-10
LID - 10.1007/s00259-013-2491-y [doi]
AB  - PURPOSE: Scintigraphy using (123)I-metaiodobenzylguanidine ((123)I-MIBG) is 
      widely used for the detection of neuroblastic tumours. The aim of this study was 
      to identify a possible correlation between the uptake intensity on (123)I-MIBG 
      SPECT and histopathology of neuroblastic tumours. METHODS: (123)I-MIBG SPECT 
      examinations were performed in 55 paediatric patients with neuroblastic tumour 
      and compared to histopathology after surgical resection or biopsy at a mean of 2 
      weeks after SPECT. For each lesion International Neuroblastoma Pathology 
      Classification System (INPC) stage, mitosis karyorrhexis index (MKI), location 
      and a semiquantitative tumour-to-liver count-rate ratio (TLCRR) were determined. 
      Also, the presence or absence of MYCN amplification, p1 deletion, urine 
      catecholamine and neuron-specific enolase blood levels at the time of scanning 
      were recorded. RESULTS: In the 55 patients, 61 lesions were evaluated with 
      (123)I-MIBG SPECT and corresponding histopathological findings were reviewed (11 
      ganglioneuroma, 11 ganglioneuroblastoma and 39 neuroblastoma). TLCRR was 
      significantly higher in the neuroblastoma group (mean TLCRR 2.7) than in the 
      ganglioneuroblastoma group (mean TLCRR 1.0) and ganglioneuroma group (mean TLCRR 
      0.7) at the time of primary diagnosis (p < 0.001) and at follow-up (p = 0.039). 
      Intense (123)I-MIBG uptake was found in tumour tissue with a high mitotic 
      activity (MKI-high or MKI-intermediate) after treatment. Four ganglioneuromas (36 
      %), three ganglioneuroblastomas (27 %) and six neuroblastomas (15 %) were 
      (123)I-MIBG-negative. CONCLUSION: In paediatric patients with peripheral 
      neuroblastic tumours, strong (123)I-MIBG uptake indicates unfavourable 
      histopathology. High uptake was seen in neuroblastomas and in tumours with a high 
      mitotic activity.
FAU - Fendler, Wolfgang Peter
AU  - Fendler WP
AD  - Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, 
      Marchioninistrasse 15, 81377, Munich, Germany, 
      wolfgang.fendler@med.uni-muenchen.de.
FAU - Melzer, Henriette Ingrid
AU  - Melzer HI
FAU - Walz, Christoph
AU  - Walz C
FAU - von Schweinitz, Dietrich
AU  - von Schweinitz D
FAU - Coppenrath, Eva
AU  - Coppenrath E
FAU - Schmid, Irene
AU  - Schmid I
FAU - Bartenstein, Peter
AU  - Bartenstein P
FAU - Pfluger, Thomas
AU  - Pfluger T
LA  - eng
PT  - Journal Article
DEP - 20130716
PL  - Germany
TA  - Eur J Nucl Med Mol Imaging
JT  - European journal of nuclear medicine and molecular imaging
JID - 101140988
RN  - 0 (Radiopharmaceuticals)
RN  - 35MRW7B4AD (3-Iodobenzylguanidine)
SB  - IM
MH  - *3-Iodobenzylguanidine/pharmacokinetics
MH  - Abdominal Neoplasms/*diagnostic imaging/pathology
MH  - Adolescent
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Infant
MH  - Male
MH  - Neuroblastoma/*diagnostic imaging/pathology
MH  - *Radiopharmaceuticals/pharmacokinetics
MH  - Tomography, Emission-Computed, Single-Photon
MH  - Young Adult
EDAT- 2013/07/17 06:00
MHDA- 2014/05/03 06:00
CRDT- 2013/07/17 06:00
PHST- 2013/03/08 00:00 [received]
PHST- 2013/06/14 00:00 [accepted]
PHST- 2013/07/17 06:00 [entrez]
PHST- 2013/07/17 06:00 [pubmed]
PHST- 2014/05/03 06:00 [medline]
AID - 10.1007/s00259-013-2491-y [doi]
PST - ppublish
SO  - Eur J Nucl Med Mol Imaging. 2013 Oct;40(11):1701-10. doi: 
      10.1007/s00259-013-2491-y. Epub 2013 Jul 16.